Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis

Journal of Infection

Volumn 55, Issue 1, 2007, Pages 68-74

  Alvarez, Carlos A ^a,b   Wiederhold, Nathan P ^a,b   McConville, Jason T ^a   Peters, Jay I ^c   Najvar, Laura K ^c   Graybill, John R ^c   Coalson, Jacqueline J ^c   Talbert, Robert L ^a,b   Burgess, David S ^a,b   Bocanegra, Rosie ^c   Johnston, Keith P ^a   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Invasive aspergillosis; Itraconazole; Prophylaxis

Indexed keywords

CORTISONE ACETATE; CYCLOPHOSPHAMIDE; ITRACONAZOLE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLUS FUMIGATUS; BAGG ALBINO MOUSE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FUNGAL COLONIZATION; HISTOPATHOLOGY; IMMUNE DEFICIENCY; KAPLAN MEIER METHOD; LUNG ASPERGILLOSIS; MOUSE; NEBULIZER; NONHUMAN; NUCLEOTIDE SEQUENCE; SURVIVAL RATE; SURVIVAL TIME;

AEROSOLS; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; LUNG; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; TREATMENT OUTCOME;

EID: 34249995115     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.01.014     Document Type: Article

References (39)

1. Denning D.W. Invasive aspergillosis. Clin Infect Dis 26 (1998) 781-803 [quiz 804-785]
2. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
3. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
4. Groll A.H., Piscitelli S.C., and Walsh T.J. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 44 (1998) 343-500
5. Sawaya B.P., Briggs J.P., and Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 6 (1995) 154-164
6. Wingard J.R., Kubilis P., Lee L., Yee G., White M., Walshe L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29 (1999) 1402-1407
7. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 1527-1533
8. Winston D.J., Maziarz R.T., Chandrasekar P.H., Lazarus H.M., Goldman M., Blumer J.L., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138 (2003) 705-713
9. Perfect J.R., Dodds Ashley E., and Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis 39 Suppl. 4 (2004) S207-S210
10. Muir D.C., and Davies C.N. The deposition of 0.5 microns diameter aerosols in the lungs of man. Ann Occup Hyg 10 (1967) 161-174
11. Edwards D.A., Ben-Jebria A., and Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 85 (1998) 379-385
12. Hoeben B.J., Burgess D.S., McConville J.T., Najvar L.K., Talbert R.L., Peters J.I., et al. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50 (2006) 1552-1554
13. NCCLS. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard [NCCLS document M38A] (2002), NCCLS, Wayne, PA
14. NAS. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington, DC
15. Rogers T.L., Hu J., Yu Z., Johnston K.P., and Williams III R.O. A novel particle engineering technology: spray-freezing into liquid. Int J Pharm 242 (2002) 93-100
16. McConville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 23 (2006) 901-911
17. Vaughn J.M., McConville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., et al. Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 63 (2006) 95-102
18. McConville J.T., Williams III R.O., Carvalho T.C., Iberg A.N., Johnston K.P., Talbert R.L., et al. Design and evaluation of a restraint-free small animal inhalation dosing chamber. Drug Dev Ind Pharm 31 (2005) 35-42
19. Sheppard D.C., Rieg G., Chiang L.Y., Filler S.G., Edwards Jr. J.E., and Ibrahim A.S. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 48 (2004) 1908-1911
20. Bowman J.C., Abruzzo G.K., Anderson J.W., Flattery A.M., Gill C.J., Pikounis V.B., et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 45 (2001) 3474-3481
21. Wiederhold N.P., Tam V.H., Chi J., Prince R.A., Kontoyiannis D.P., and Lewis R.E. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50 (2006) 469-473
22. Costa C., Vidaud D., Olivi M., Bart-Delabesse E., Vidaud M., and Bretagne S. Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum. J Microbiol Methods 44 (2001) 263-269
23. Klepser M.E. Amphotericin B in lung transplant recipients. Ann Pharmacother 36 (2002) 167-169
24. Dummer J.S., Lazariashvilli N., Barnes J., Ninan M., and Milstone A.P. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 23 (2004) 1376-1381
25. Drew R.H., Dodds Ashley E., Benjamin Jr. D.K., Duane Davis R., Palmer S.M., and Perfect J.R. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232-237
26. Allen S.D., Sorensen K.N., Nejdl M.J., Durrant C., and Proffit R.T. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 34 (1994) 1001-1013
27. Ruijgrok E.J., Vulto A.G., and Van Etten E.W. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 48 (2001) 89-95
28. Gavalda J., Martin M.T., Lopez P., Gomis X., Ramirez J.L., Rodriguez D., et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 49 (2005) 3028-3030
29. Chamilos G., Luna M., Lewis R.E., Bodey G.P., Chemaly R., Tarrand J.J., et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91 (2006) 986-989
30. Hachem R.Y., Kontoyiannis D.P., Boktour M.R., Afif C., Cooksley C., Bodey G.P., et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101 (2004) 1594-1600
31. Paterson P.J., Seaton S., Prentice H.G., and Kibbler C.C. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 52 (2003) 873-876
32. Steinbach W.J., Benjamin Jr. D.K., Kontoyiannis D.P., Perfect J.R., Lutsar I., Marr K.A., et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39 (2004) 192-198
33. MacCallum D.M., Whyte J.A., and Odds F.C. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 49 (2005) 3697-3701
34. Petraitis V., Petraitiene R., Sarafandi A.A., Kelaher A.M., Lyman C.A., Casler H.E., et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 187 (2003) 1834-1843
35. Lewis R.E., Prince R.A., Chi J., and Kontoyiannis D.P. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46 (2002) 3208-3214
36. Meletiadis J., Petraitis V., Petraitiene R., Lin P., Stergiopoulou T., Kelaher A.M., et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 194 (2006) 1008-1018
37. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
38. Marr K.A., Leisenring W., Crippa F., Slattery J.T., Corey L., Boeckh M., et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 103 (2004) 1557-1559
39. Cacciapuoti A., Loebenberg D., Corcoran E., Menzel Jr. F., Moss Jr. E.L., Norris C., et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 44 (2000) 2017-2022